BAGSVAERD, DENMARK--(Marketwire - May 18, 2009) - Novo Nordisk A/S - Share repurchase programme
On 29 January 2009 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009.
Since the announcement as of 11 May 2009, the following transactions have been made under the programme:
Number of Average purchase Transaction
shares price value, DKK
Accumulated, last
announcement 5,782,182 1,594,199,578
11 May 2009 90,000 270.82 24,373,800
12 May 2009 90,000 273.70 24,633,000
13 May 2009 95,000 280.40 26,638,000
14 May 2009 75,000 277.61 20,820,750
15 May 2009 90,000 278.54 25,068,591
Accumulated under
the programme 6,132,182 1,690,665,128
Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 17,600 B shares in the period from 11 May to 15 May. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 30,932,425 treasury shares, corresponding to 4.9% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares.
The Annual General Meeting of Novo Nordisk A/S, which was held on 18 March 2009, approved a 2.2% reduction in the total share capital by cancellation of 14,000,000 treasury B shares of DKK 1 at a nominal value of DKK 14,000,000. After the legal implementation of the share capital reduction, which is expected to take place after expiry of the legal notice period in June 2009, Novo Nordisk's share capital will amount to DKK 620,000,000 divided into an A share capital of DKK 107,487,200 and a B share capital of DKK 512,512,800. Taking into account the expected cancellation Novo Nordisk would currently own 2.7% of such reduced share capital.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
Further information: Media: Investors: Outside North America: Outside North America: Elin K Hansen Mads Veggerby Lausten Tel: (+45) 4442 3450 Tel: (+45) 4443 7919 ekh@novonordisk.com mlau@novonordisk.com Kasper Roseeuw Poulsen Tel: 4442 4471 krop@novonordisk.com In North America: In North America: Sean Clements Hans Rommer Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937 secl@novonordisk.com hrmm@novonordisk.com
Company Announcement no 28 / 2009
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
